hBD-1 vs Larazotide
Head-to-head comparison of hBD-1 (Human beta-defensin 1) and Larazotide (Larazotide acetate (AT-1001)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | hBD-1 | Larazotide |
|---|---|---|
| Category | Dental & Oral | Gastrointestinal |
| Full Name | Human beta-defensin 1 | Larazotide acetate (AT-1001) |
| Molecular Weight | 4490 Da | N/A |
| Half-Life | minutes to hours | short; designed for local gut action |
| Amino Acids | 36 | 8 |
| Typical Dose | 1-10 µg/mL in experimental studies | 0.5-4 mg TID (clinical studies) |
| Route | Topical/Intraoral | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 85 | 40 |
| Research Status | Pre-clinical | Clinical |
hBD-1 Benefits
- ✓oral innate immunity
- ✓broad antimicrobial activity
- ✓biofilm suppression
- ✓periodontal support
Larazotide Benefits
- ✓tight-junction-support
- ✓reduced-permeability
- ✓symptom-reduction
- ✓barrier-protection
hBD-1 Dosing
topical peptide exposure|cell-culture or mucosal models|repeat low-dose application in research
Larazotide Dosing
0.5-4 mg orally before meals in clinical trials|typically three times daily|short-course or chronic study protocols
hBD-1 Side Effects
- ⚠protease degradation
- ⚠local irritation at high dose
- ⚠limited stability in saliva
Larazotide Side Effects
- ⚠headache
- ⚠nausea
- ⚠abdominal discomfort
Research Overview
hBD-1
hBD-1 has been studied as part of the oral mucosal defense system and is linked to host resistance against dental pathogens. Research spans periodontitis, candidiasis, and epithelial barrier biology.
Larazotide
Clinical and translational studies suggest larazotide can reduce antigen passage across the epithelium and improve gut barrier function. It is one of the better-known peptides for intestinal permeability and barrier-focused gastrointestinal therapy.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.